[go: up one dir, main page]

NO20051956L - Salmeterol superfin formulering - Google Patents

Salmeterol superfin formulering

Info

Publication number
NO20051956L
NO20051956L NO20051956A NO20051956A NO20051956L NO 20051956 L NO20051956 L NO 20051956L NO 20051956 A NO20051956 A NO 20051956A NO 20051956 A NO20051956 A NO 20051956A NO 20051956 L NO20051956 L NO 20051956L
Authority
NO
Norway
Prior art keywords
formulation
relates
salmeterol
superfine formulation
superfine
Prior art date
Application number
NO20051956A
Other languages
English (en)
Other versions
NO20051956D0 (no
Inventor
David Ganderton
Brian John Meakin
Gaetano Brambilla
David Andrew Lewis
Tanya Kathleen Church
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32087950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051956(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO20051956D0 publication Critical patent/NO20051956D0/no
Publication of NO20051956L publication Critical patent/NO20051956L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører en farmasøytisk formulering for anvendelse i administrasjonen av en langtidsvirkende P2-agonist ved inhalasjon. Spesielt vedrører denne oppfinnelse en kjemisk stabil, høyst effektiv salmeterol-HFA løsningsformulering som skal administreres av trykksatte doserte doseinhalatorer (PMDIer) kjennetegnet ved en dyp lungepenetrasjon. Oppfinnelsen vedrører også fremgangsmåter for fremstillingen av formuleringen og dens anvendelse i respiratoriske sykdommer slik som astma og kronisk obstruktiv lungesykdom (KOL).
NO20051956A 2002-10-23 2005-04-21 Salmeterol superfin formulering NO20051956L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02023589A EP1415647A1 (en) 2002-10-23 2002-10-23 "Long-acting beta-2 agonists ultrafine formulations"
PCT/EP2003/006444 WO2004037227A1 (en) 2002-10-23 2003-06-18 Salmeterol superfine formulation

Publications (2)

Publication Number Publication Date
NO20051956D0 NO20051956D0 (no) 2005-04-21
NO20051956L true NO20051956L (no) 2005-07-22

Family

ID=32087950

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051956A NO20051956L (no) 2002-10-23 2005-04-21 Salmeterol superfin formulering

Country Status (12)

Country Link
US (1) US8088362B2 (no)
EP (2) EP1415647A1 (no)
AR (1) AR040450A1 (no)
AT (1) ATE421875T1 (no)
AU (1) AU2003245965A1 (no)
BR (1) BR0306663A (no)
CA (1) CA2503183C (no)
DE (1) DE60326053D1 (no)
ES (1) ES2319887T3 (no)
NO (1) NO20051956L (no)
PE (1) PE20040314A1 (no)
WO (1) WO2004037227A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EP1273292B1 (en) * 2001-07-02 2004-05-26 CHIESI FARMACEUTICI S.p.A. Optimised formulation of tobramycin for aerosolization
EP1415647A1 (en) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP2086617A4 (en) * 2006-10-26 2013-11-20 Next Breath Llc INHALATION SYSTEM BASED ON PHOSPHOLIPIDS
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
US20130274232A1 (en) 2010-07-16 2013-10-17 Cipla Limited Pharmaceutical Compositions
WO2020070620A2 (en) * 2018-10-01 2020-04-09 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
WO2021216779A1 (en) * 2020-04-21 2021-10-28 Amphastar Pharmaceuticals, Inc. Anti-viral pharmaceutical formulations administered via devices for lung targeted delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
AP960A (en) * 1995-04-14 2001-04-20 Glaxo Wellcome Inc Metered dose inhaler for fluticasone propionate.
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6585958B1 (en) * 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20050048001A1 (en) * 1999-11-23 2005-03-03 Cripps Alan Leslie Pharmaceutical formulations of salmeterol
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
SE0004750D0 (sv) * 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US6455028B1 (en) * 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
PT3494995T (pt) 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
EP1415647A1 (en) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1340492A1 (en) 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
EP1415647A1 (en) 2004-05-06
BR0306663A (pt) 2004-10-19
WO2004037227A1 (en) 2004-05-06
DE60326053D1 (de) 2009-03-19
EP1553922B1 (en) 2009-01-28
CA2503183C (en) 2011-06-14
PE20040314A1 (es) 2004-07-05
NO20051956D0 (no) 2005-04-21
ES2319887T3 (es) 2009-05-14
EP1553922A1 (en) 2005-07-20
ATE421875T1 (de) 2009-02-15
CA2503183A1 (en) 2004-05-06
US20060120966A1 (en) 2006-06-08
AR040450A1 (es) 2005-04-06
AU2003245965A1 (en) 2004-05-13
US8088362B2 (en) 2012-01-03

Similar Documents

Publication Publication Date Title
TNSN04147A1 (en) Formoterol superfine formulation
NO20051956L (no) Salmeterol superfin formulering
AR101593A2 (es) Formulación superfina de formoterol
ECSP024268A (es) Nuevos polvos para inhalacion que contienen tiotropio
UY31235A1 (es) Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
NO20053548L (no) Pulvermedikament for inhalering inneholdende et tiotropiumsalt og salmeterolxinafoat.
EA201401354A1 (ru) Новая дозированная форма и препарат, содержащий абедитерол
SG149876A1 (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
MY143364A (en) Method for producing tiotropium salts
UY28096A1 (es) Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación
KR101995612B1 (ko) 만성 폐색성 폐질환 개선제
IL163736A (en) Tiotropium containing powdered preparations, method of their preparation and uses thereof for the manufacture of a medicament suitable for inhalation
TH66681A (th) สูตรผสมที่ละเอียดเป็นพิเศษของฟอร์มอเทอรอล

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application